Format

Send to

Choose Destination
Front Mol Neurosci. 2019 Jan 7;11:483. doi: 10.3389/fnmol.2018.00483. eCollection 2018.

A Strategy for Discovery and Verification of Candidate Biomarkers in Cerebrospinal Fluid of Preclinical Alzheimer's Disease.

Author information

1
School of Pharmacy, University of Wisconsin-Madison, Madison, WI, United States.
2
Neuroscience Training Program, University of Wisconsin-Madison, Madison, WI, United States.
3
School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States.
4
Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
5
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
6
Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.
7
UK Dementia Research Institute at UCL, London, United Kingdom.
8
Department of Chemistry, University of Wisconsin-Madison, Madison, WI, United States.

Abstract

Alzheimer's disease (AD), a progressive neurodegenerative disease, is characterized by the accumulation of senile plaques, neurofibrillary tangles, and loss of synapses and neurons in the brain. The pathophysiological process of AD begins with a long asymptomatic phase, which provides a potential opportunity for early therapeutic intervention. Therefore, it is crucial to define putative biomarkers via reliable and validated methods for early diagnosis of AD. Here, we characterized candidate biomarkers by discovery proteomics analysis of cerebrospinal fluid (CSF), revealing that 732 and 704 proteins with more than one unique peptide were identified in healthy controls and preclinical AD patients, respectively. Among them, 79 and 98 proteins were significantly altered in preclinical AD for women and men, respectively, many of which have been demonstrated with consistent regulation pattern in patients with mild cognitive impairment or AD dementia. In-house developed 5-plex isotopic N,N-dimethyl leucine (iDiLeu) tags were further utilized to verify candidate biomarkers, neurosecretory protein VGF (VGF) and apolipoprotein E (apoE). By labeling peptide standards with different iDiLeu tags, a four-point internal calibration curve was constructed to allow for determination of the absolute amount of target analytes in CSF through a single liquid chromatography-mass spectrometry run.

KEYWORDS:

Alzheimer’s disease; biomarker; cerebrospinal fluid; iDiLeu; isotopic labeling for quantitation; label-free quantitation; targeted quantitative proteomics

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center